Health Care Cost

As prescription drug affordability boards move toward upper payment limit implementation, uncertainties introduced across the health care system and risks to patient access warrant urgent attention.

Carl Regillo, MD, on missed wet AMD injections, treatment switching, and how gene therapy could ease chronic burden.

Slated to run through December 31, 2027, the Medicare GLP-1 Bridge was originally supposed to run for only 6 months.

A secret shopper study found 9 in 10 online GLP-1 sellers issued prescriptions, often with minimal screening for eating disorders or clinical risk.

The authors used Medicaid claims data to quantify program spending, use of services, and enrollment patterns among Medicaid beneficiaries newly diagnosed with a metastatic vs a nonmetastatic cancer.

The Pediatric Cancer Research Foundation calls for systemic change as pediatric cancer creates long-term financial burdens extending through survivorship.

Carl Regillo, MD, explains why wet AMD anti‑VEGF results lag in real life and how newer agents extend dosing, yet the burden persists.

The House passed HR 5347 to extend flexible Medicare ACO quality reporting and support smaller practices transitioning to digital measures.

Senate Democrats introduced a bill to cap out-of-pocket costs at $5000 for traditional Medicare beneficiaries and expand low-income assistance.

National HIV Testing Day highlights how state policies, pharmacists, and long-acting therapies are reshaping access to HIV testing, PrEP, and PEP.

Obesity coding gaps limit care; MCL rising in women; racial pain disparities in oncology; AML access expands; SDOH rivals genetics.

New research reveals complex treatment costs from MM strain patients and caregivers during active therapy, while pain goes undertreated at end of life.

A single-center study found low rates of MRA and SGLT2 inhibitor prescribing among low-income, largely uninsured patients with heart failure.

Deloitte's Pete Lyons explains the confidence gap, diverging biopharmaceutical and medical technology risks, and what separates real AI value from activity.

Spending on health expenditures will make up 20.6% of gross domestic product, according to a federal report.

Deloitte's midyear analysis shows internal confidence rising even as external uncertainty over policy, tariffs, and reimbursement persists for biopharma and medtech.

More short-term injections were needed to maintain visual outcomes in patients who lost their co-payment assistance.

Texas abortion ban worsens maternal mental health; SCD trials exclude 90% of adults; nutrition, hepatitis B, and cost-control gaps persist.

Robert Andrews, CEO, Healthcare Transformation Alliance, provides insight on what workers' compensation tells us about managing health care costs.

David Brueggeman, MBA, breaks down the underpriced financial risks, redetermination lessons, and what accountable AI actually requires from health plans.

FDA approved Rextovy, a 4-mg OTC naloxone nasal spray, expanding access to opioid overdose reversal medications nationwide.

Broader cancer care networks were not consistently associated with lower Medicare Advantage disenrollment after cancer diagnosis.

Commercial health care costs are projected to grow 9% in 2027, driven by AI billing tools, pharmacy spend, and provider consolidation, per a PwC report.

A CMS proposed rule would make the Medicare Drug Price Negotiation Program permanent, covering up to 20 drugs per year starting in 2029.

Worse kidney function and higher proteinuria at biopsy predicted significantly greater health care use over 2 years in patients with IgA nephropathy.